Introduction
There is increasing interest in exploring the possibility that inter-individual epigenetic variation plays a role in common human disease aetiology (Reviewed in Rakyan et al. 2011; Petronis 2010) Consequently, Epigenome-wide association studies (EWASs), analogous to genome-wide association studies (GWASs) for disease-associated genetic variants (Rakyan et al. 2011) , are currently being conducted to systematically uncover epigenetic variants for a range of different diseases (www.roadmapepigenomics.org/participants lists some of the current NIH-funded EWASs). However, the disease process itself can also induce epigenetic changes. Therefore, an EWAS design that just compares post-disease affected with unaffected individuals will not distinguish causal from consequential disease-associated epigenetic variation. The inability to make this distinction will ultimately prove to be a significant barrier to establishing the aetiological role or medical value for any disease-associated epigenetic variants.
One way of addressing this issue is to determine whether the epigenetic variants are detectable before overt disease. Although such variants could arise at any point during an individual's lifespan (Fraga et al. 2005) , in utero development is considered to be a period during which the epigenome is particularly susceptible to stochastic and/or environmental factors such as infection, poor diet, or stress (Reviewed in Warner and Ozanne 2010) . A variety of common diseases have been proposed to have a component of in utero origins including asthma, metabolic conditions including type 2 diabetes, and autoimmune disorders like multiple sclerosis (Warner and Ozanne 2010; Heijmans et al. 2008) . Hence, being able to determine epigenomic profiles at birth, and by implication before overt disease, would be invaluable for elucidating the origins and potentially the aetiological role of disease-associated epigenetic variants. In this regard, prospective birth-cohort Cold Spring Harbor Laboratory Press on August 23, 2012 -Published by genome.cshlp.org Downloaded from 3 studies are very useful but, unfortunately, are expensive, time-consuming, and difficult to establish.
In 1963, Robert Guthrie proposed spotting a small amount of neonatal blood onto filter paper for the large-scale biochemical screening of various diseases such as phenylketonuria (Guthrie and Susi 1963) . 'Guthrie cards' are now routinely created by major national health authorities e.g. since 2000, over 90% of all neonates in the United States had Guthrie cards made shortly after birth (Pollitt 2009 ). Remarkably, in many cases Guthrie cards are being stored indefinitely. This led us to consider genome-wide DNA methylation profiling -DNA methylomics -of Guthrie cards as a means of investigating the origins of disease-associated epigenetic variation. Crucially, this longitudinal investigation could be done retrospectively at a fraction of the cost and time investment required for prospective studies.
Results
Our first objective was to confirm that Guthrie cards could be used to generate high-quality DNA methylomes. We obtained Guthrie cards from the Diabetes Prediction in Skåne (DiPiS) study (Larsson et al. 2004 ). These cards were spotted with cord blood in September 2000 (Methods). Of several different protocols, we found the Gensolve kit provided the highest genomic DNA (gDNA) yields from Guthrie cards (data not shown). A typical Guthrie card consists of four ~6mm diameter blood spots and we routinely obtained approximately 200 ng of gDNA per spot (Fig. 1) . Although Guthrie card gDNA was of a slightly lower molecular weight compared with gDNA from freshly sampled cord blood, significant degradation was minimal (Supplementary Fig. 1 ). We then validated two different platforms for DNA methylomics, each offering different advantages: Illumina 450K arrays (Sandoval et al. 2011 , Bibikova et al. 2011 , and Methylated DNA Immunoprecipitation combined with HTS (MeDIP-seq) (Weber et al. 2005; Down et al. 2008) .
The Illumina450K array is a genome-scale platform that provides bisulfite conversion-based, single base resolution methylation measurements at ~450,000 different cytosines associated with a range of genomic features such as promoters, enhancers, and CpG islands (CGIs) (Sandoval et al. 2011 ). We generated biological duplicate Illumina450K profiles for Guthrie cards, freshly sampled cord blood, and mature sperm, all from unrelated individuals (Supplementary Table 1 ).
Comparison of Illumina450K-based 'fresh blood vs. sperm' tissue-specific differentially methylated regions (tDMRs) with 'blood vs. sperm' tDMRs identified by bisulfite PCR sequencing in the Human Epigenome Project (Eckhardt et al. 2006 ) revealed a high correlation (R 2 = 0.90, Pearson's, Fig.   2a ). Importantly, a comparison between Illumina450K-based fresh blood and Guthrie card profiles also revealed an excellent correlation (R 2 = 0.99, Pearson's) (Fig. 2b) . However, in both cases, the correlation was significantly weaker for tDMR methylation differences of <20% (R 2 for <20% methylation differences = 0.50, Pearson's), and thus we set a conservative minimum threshold of ≥20% methylation difference for calling inter-sample DMRs in the analyses described below (in the Cold Spring Harbor Laboratory Press on August 23, 2012 -Published by genome.cshlp.org Downloaded from 4 rest of the manuscript, when we state "% methylation difference", we mean an absolute difference in the beta value X 100). To further confirm the quality of Guthrie card methylomes, we compared canonical gene-associated DNA methylation profiles for both CGI and non-CGI associated genes between Guthrie cards and fresh blood and found the profiles to be virtually identical for the two different types of samples (Supplementary Fig. 2 ).
In MeDIP-seq, immunoprecipitated methylated DNA fragments are subjected to HTS, representing a cost-effective strategy for generating whole-genome DNA methylomes at approximately 50bp resolution (Down et al. 2008) . For Guthrie cards analysis, we developed a MeDIP-seq protocol for 200 ng of gDNA (Methods). We also generated standard MeDIP-seq libraries using 2 µg of DNA from fresh cord blood and sperm (Supplementary Table 1 ). The MeDIP-seq data were then compared with the Illumina450K-based profiles described above (Fig. 2c) . Because MeDIP enrichment of a genomic region is dependent on the density of methylated CpG sites, standard measures of correlation are not suitable, and instead we calculated an 'agreement' score: the percentage of Illumina450K-based DMRs that show the same directional differences in MeDIP-seq read counts between the two samples under consideration. Very good agreement scores (75 -93%) were observed between Illumina450K and MeDIP-seq datasets across a range of CpG densities. A similar analysis using Guthrie card vs. sperm MeDIP-seq-based tDMRs yielded equally strong agreement with Illumina450K data (Fig. 2c) .
Our second objective was to determine the potential utility of Guthrie cards for studying human inter-individual epigenetic variation. If in utero-derived epigenomic perturbations can impact on phenotypic outcomes in later life, then there must be some inter-individual epigenetic variants that are detectable at birth and temporally stable. To obtain evidence for the existence of such epigenetic variants, we conducted an integrated methylomic/genomic analysis of Guthrie cards and follow-up samplings as outlined in Fig. 3a . We obtained Guthrie cards spotted with cord-blood from three unrelated individuals (two females and one male) from the DiPiS study and generated Illumina450K-based DNA methylomes. For each of the three different pair-wise comparisons, we found ~2,000 -3,000 CpG sites that displayed inter-individual DNA methylation differences of >20% (Fig. 3b , sex chromosomes were excluded from all analyses). We then filtered these lists to reduce the influence of artefactual methylation measurements and inter-individual genetic variation (Table 1) . To this end, we first generated genome-wide single nucleotide polymorphism (SNP) profiles for all three individuals using their Guthrie card DNA. SNP profiling was done using the Illumina Omni2.5S array that contains ~2.5 million SNPs with a minor allele frequency of down to 1%. Using these data, we applied three main filters to each of the three different pair-wise lists of inter-individual single CpG methylation differences: (i) excluded those CpGs that overlapped single nucleotide polymorphisms (SNPs) or were located within a copy number variant (CNV). This eliminates artefactual measurements that are not methylation differences, but rather due to the Cold Spring Harbor Laboratory Press on August 23, 2012 -Published by genome.cshlp.org Downloaded from creation/destruction of CpGs or differences in copy number, an issue rarely addressed in complex disease epigenomics; (ii) As the biological relevance of methylation differences limited to single CpG sites is presently unclear, for the second filter we specified that the CpG must exist as part of a differentially methylated region (DMR), i.e. neighbouring CpGs within a 250bp window of the index CpG site must also display >20% methylation differences in the same direction; (iii) Recently, Bell and colleagues identified 180 different CpGs in the human genome whose methylation state in lymphoblastoid cells is influenced by genetic variation (Bell et al. 2011) . Crucially, in the vast majority of cases they found the genetic influence to act in cis and <5kb from the CpG site of interest. Therefore, for the third filter, we retained only those DMRs that are located within a ≥ 10kb window that does not contain any SNP differences, as measured by the Illumina Omni2.5S SNP array, in the pair-wise comparison under consideration. This reduces the likelihood of interindividual genetic differences being the sole drivers of the DMRs (although in a few cases rare genetic variants missing from the SNP arrays would be overlooked). Overall, application of the filters resulted in a final set of 10 -13 different inter-individual DMRs per pairwise comparison ( Fig.   3b and Table 2 ). Given the stringency of our filters, this is almost certainly an under-estimate of the level of inter-individual DNA methylation variation that exists between any two unrelated human individuals.
Then, to establish the temporal stability of the DMRs found using Guthrie cards (i.e. at birth), we generated MeDIP-seq profiles of whole blood sampled from the same individuals when they were 3 years old (all individuals were disease free at the time of sampling). Since we did not have access to 500ng of gDNA required to perform 450K analysis on the follow-up samples, we used the MeDIP-seq method for 200ng of gDNA as described above. Given the differences in platformspecific biases, the eventual results would, if anything, be an underestimate of the number of temporally stable epialleles that exist in the individuals under study. MeDIP-seq sequencing statistics are provided in the Supplementary section. Comparison between the final set of 'at birth' Illumina450K-based inter-individual DMRs with MeDIP-seq profiles of the same individuals at 3 years old yielded agreement scores ranging from 70 -91% (Fig. 3b) . This demonstrates, for the first time, the existence of temporally stable inter-individual epigenetic variation that is present at birth. These DMRs were found across the genome, associated with a variety of genomic elements including promoters and CGIs, but also intergenic regions (Table 2) . Interestingly, a few DMRs were located within genes associated with human diseases e.g. FZD1 expression is down regulated in ulcerative colitis (Hughes et al. 2011) , and NFIA has been associated with coeliac disease (Dubois et al. 2010) . It is also worth noting the large difference in agreement scores between the unfiltered (52 -55% i.e. marginally better than random) and post-filtered data (70 -91%). This suggests that future epigenomic investigations should integrate epigenetic and genetic variation data to optimise the biological relevance and reduce false positive 'epigenetic' discoveries.
Cold
Discussion
A significant challenge in EWASs will be distinguishing causal from consequential epigenetic variation, and using solely 'case vs. control' study designs will not help to address this issue.
Rather, as has been recently discussed (Rakyan et al. 2011) , effective EWASs will need to combine different types of cohorts, among which longitudinal cohorts in particular will be invaluable. Guthrie card DNA methylomics therefore has the potential to become a valuable component of EWASs for a range of common diseases. and these numbers will only increase. In terms of potential limitations, Guthrie cards are restricted to whole blood that represents a heterogeneous population of cells. But this is also typically the case in large-scale prospective studies in which, for logistical reasons, it is only possible to sample tissues such as whole blood or buccals. However, since in utero events are thought to impact on more than one tissue, Guthrie cards are likely to be informative for the epigenetics of a range of diseases that affect multiple blood subtypes and possibly even non-blood tissues. Although one could argue that prospective studies are likely to obtain more detailed information about life-style factors, Guthrie cards could still be used to establish whether disease-associated DNA methylation variants are present at birth, providing a crucial starting point for further research, including investigating the possibility of using epigenetic variants, in combination with genetics, as predictive markers. Finally, the vast numbers of Guthrie cards that currently exist provide a pool of material to study a large range of diseases. It is also worth noting that spotting blood on filter paper is not limited to neonatal screening, but could also be more widely applied in home/field-based settings.
Using Guthrie cards, we were able to identify temporally stable epialleles that are present at birth in humans, demonstrating a key application of Guthrie card methylomics. The identified DMRs described above must have been present in utero since they were identified at birth. Given the filters we applied to the data, the DMRs are more likely due to environmental or stochastic interindividual differences within the in utero milieu (e.g. differences in maternal diet) rather than solely genetic differences. Indeed, even though ~95% of the CpGs assayed by Illumina27K arrays are
Cold Spring Harbor Laboratory Press on August 23, 2012 -Published by genome.cshlp.org Downloaded from 7 also represented on the Illumina450K array (Bell et al. 2011) , none of the CpGs they identified, at which the methylation state is influenced by cis-genetic variation, overlap our final filtered list of DMRs. However, to unequivocally rule out genetic differences, extensive re-sequencing of the DMRs would be required, which was not feasible for our proof-of-principle study, but should be performed in future larger-scale EWASs. Although in this study we focussed on identifying epigenetic alterations that are less likely to be due to genetic heterogeneity, Guthrie card methylomics will also be useful for studying genotype-epigenotype interactions. Recently, it has been shown that genetic influences on epigenetic states in the human genome can be probabilistic i.e. there isn't a strict one-to-one relationship between genotype and epigenotype but rather a certain probability at which a given epigenetic state will arise (Feinberg and Irizarry 2010) . Such regions have been termed 'variably methylated regions' or VMRs (Feinberg and Irizarry 2010) .
VMRs show similar properties to 'metastable epialleles' previously described in mice (Morgan et al. 1999; Rakyan et al. 2003) and humans (Waterland et al. 2010) , at which the establishment of the epigenetic state occurs during early development in a probabilistic manner. Therefore, if genetically-influenced probabilistic establishment of epigenetic state occurs during embryogenesis, then knowing the epigenetic state at birth would be invaluable for understanding the biological impact and the predicting the phenotypic outcomes of such genetic variants.
In summary, Guthrie cards will allow retrospective investigations into the temporal origins of epigenetic variants, and potentially help elucidate their aetiological role. Robert Guthrie envisaged that such cards would eventually find many uses for understanding and ultimately preventing human diseases (6); the application to complex disease epigenomics would be a novel and powerful use of this remarkable resource.
COMPETING FINANCIAL INTERESTS
The authors declare that they have no competing financial interests.
METHODS
Samples. Guthrie card and fresh cord blood samples were obtained from the DiPiS (Diabetes Prediction in Skåne) study (Supplementary Table 1 were collected into EDTA tubes at Malmö University Hospital, Lund University, and processed within 24 hours. For the samplings of the 3 year old children, venous EDTA blood sample was obtained at a Community Health Centre. The EDTA blood was immediately added to the Guthrie card in three droplets and allowed to dry before being mailed overnight in a page protector to the Isolation of genomic DNA from Guthrie cards. Guthrie card gDNA was extracted using the GenSolve kit as per the manufacturer's instructions (www.genvault.com/html/products). Following extraction, the samples were further purified using the Qiagen QiaAmp mini columns and eluted in 100 µl of elution buffer. DNA concentration was determined using a Qubit instrument (Invitrogen).
Generation and analysis of array-and HTS-based data. Illumina450K arrays were processed according to the manufacturer's instructions using 500ng of DNA. The data quantile normalized and resulting beta values used in downstream analyses. MeDIP-seq libraries were prepared using a modified version of the protocol described in Reference 13, and sequenced on an Illumina GAIIx instrument (v4 chemistry). One lane of 36bp paired-end sequencing was performed for each MeDIP-seq library. A detailed description is provided in Supplementary Methods. MeDIP-seq reads were aligned and processed using bwa 0.5.9 ), samtools 0.1.7 (Li and Durbin 2009 ) and custom scripts (available upon request). After alignment and deduplication, we selected all read pairs with a mapping score ≥ 10. Within each group of samples (guthrie cards and fresh blood) we calculated histograms of read-pair spacings (insert sizes) then randomly discarded some reads from each library in order to perfectly match the insert-size distributions within the group. We then counted numbers of read pairs overlapping 500bp windows centred around the target CpG site of each probe on the Illumina450K array. It is worth noting that we did not perform DMR calling per se on the MeDIP-seq data, but rather asked if the difference between read counts in the two samples was positive or negative. So read/tag depth only affects agreement score to the extent that signal/noise ratio will tend to be higher in region with high read depths. Since MeDIP enrichment efficiency depends on the number of meCpGs per fragment, this will tend to be higher when methylation occurs in the context of CpG dense regions. Illumina Omni2.5S arrays (www.illumina.com) were processed according to the manufacturer's instructions using 200 ng of Guthrie card DNA.
Statistical analyses. For all correlation analyses among the different methylomic datasets,
Pearson's correlation coefficient was selected as it is a familiar descriptive measure of the similarity between two quantitative datasets and has been previously used in the context of DNA methylomics (Down et al. 2008 ).
Processing of HEP data. HEP bisulfite data for sperm, CD4+ and CD8+ T-cells was downloaded
Cold Spring Harbor Laboratory Press on August 23, 2012 -Published by genome.cshlp.org Downloaded from from the website. This includes amplicon coordinates (NCBI34) and methylation ratios for each CpG covered by each bisulfite PCR sequencing read of the HEP dataset. Since some amplicons have low coverage, we selected only those amplicons which, for each of CD4+, CD8+, and Sperm, have at least two reads of data, and have coverage for at least 5 separate CpG sites. Also, to avoid double counting (i.e. where two HEP amplicons overlapped in our dataset) we excluded the smaller of the overlapping amplicons from further analyses. For each amplicon that fulfilled these criteria, we took the mean of all CpG methylation ratios for each cell type. As an additional quality control measure (and also to exclude some HEP amplicons which are highly variable between different blood cell types) we discarded amplicons with a >10% methylation difference between CD4+ and CD8+ cells. We then took the mean of the CD4+ and CD8+ methylation ratios to give a combined 'Blood' methylation value.
Additional Methods. Detailed Methodology is described in the Supplementary Methods. 
